Research is indispensable to advancing care for systemic amyloidosis. Systemic amyloidosis develops when a protein made by the body misfolds and forms cytototoxic aggregates, together with fibrils, that build up in tissues and impair organ function. Several different proteins can form amyloid in the same organ. Finding out which protein is responsible, and how far the disease has progressed, guides both the choice and the timing of treatment.
In 1986, Giampaolo Merlini founded the Amyloidosis Research and Treatment Center at the Policlinico San Matteo in Pavia. The center, now directed by Giovanni Palladini, brought specialists from the hospital and scientists from the University of Pavia into the same clinical and research program. Patients whose disease affected several organs could be followed by a team. Laboratory scientists could investigate the molecular mechanisms underpinning these diseases.
Identifying the protein
An early example came from a family with inherited amyloidosis that primarily affected the heart. In 1999, the Pavia investigators identified a variant of apolipoprotein A-I, a protein that helps carry cholesterol in the blood, and showed that a fragment of it formed the fibrils in the heart. They subsequently identified a different variant in several families, particularly in Northern Italy, with prominent kidney, liver and testis involvement. Establishing the cause explained why the illness ran in these families and made it possible to offer relatives a specific genetic test.
Pavia researchers also worked to identify proteins from a small sample. They used mass spectrometry to identify the proteins in amyloid deposits from abdominal fat collected with a needle. In a prospective study of 745 people with suspected systemic amyloidosis, the ARTC investigators evaluated another approach, using antibodies to identify the deposited protein under an electron microscope. How often the method detected amyloid depended on the type of disease. When it identified the protein in a fat sample, a patient could often avoid a biopsy of the affected organ.
Deposits obtained from patients also made it possible to study how the fibrils are built. In 2019, teams in Pavia and Milan, used cryo-electron microscopy to resolve the structure of light-chain fibrils extracted from a patient’s heart. Seeing how fragments of the light chain fit together at molecular scale gives researchers a way to ask which parts of a deposit a therapeutic antibody could recognize.
Measuring and treating light chain amyloidosis
In light-chain amyloidosis, or AL amyloidosis, a clone of plasma cells in the bone marrow makes identical light chains, proteins that normally form part of an antibody. Even small plasma cell clones, which are per se innocuous, can cause devastating, fatal, multi-organ damage via the immunoglobulins they produce. The novel concept of small dangerous B cell clones was introduced by Merlini and Stone in 2006. The paper fundamentally reshaped how hematologists classify and approach monoclonal gammopathies by shifting focus away from tumor burden (how many clonal cells exist) toward protein toxicity (the destructive physical or immunological properties of the monoclonal protein itself). In 2009, the ARTC investigators showed that measuring free light chains in the blood and using immunofixation, a method for detecting abnormal antibody proteins, in both blood and urine improved detection of the abnormal protein. Identifying the protein in the deposits can then establish whether the plasma-cell disorder accounts for the amyloidosis.
The heart posed a different problem. In 2003, the Pavia team showed that NT-proBNP, a blood marker of cardiac strain, could help detect early cardiac involvement and predict survival. Three years later, the team found that NT-proBNP could fall soon after treatment, alongside a reduction in circulating light chains, even when heart wall thickness had changed little or not at all on ultrasound. The fall of NT-proBNP was associated with a survival benefit. This observation suggested that soluble light chains could themselves harm the heart. Subsequent laboratory studies explored how this might happen, including effects on mitochondria, the structures that supply cells with energy. The ARTC investigators, in collaboration with investigators of the Mario Negri Institute, developed in 2014 a reliable animal model to investigate the cardiotoxicity of amyloid light chains, which illuminated the role of oxidative stress and consequent mitochondrial damage caused by amyloid light chains in determining cardiotoxicity.
In 2012, Palladini and Colleagues in Europe and the United States used free light chains and cardiac biomarkers to define treatment responses and showed how these responses related to survival. In 2014, a collaboration between Pavia and Heidelberg, used the amount of protein lost in the urine and the kidneys’ filtering capacity to estimate the risk of dialysis and assess kidney response. Clinicians could judge a patient’s response very rapidly, within months of starting therapy, optimizing treatment, and research teams could use the same definitions in trials across centers.
Pavia helped develop the treatments whose effects it was learning to measure. In 2004, Palladini and Colleagues reported that melphalan and dexamethasone could reduce light-chain, improve cardiac function, and improve survival in patients ineligible for stem cell transplantation. This regimen was the standard of care for AL amyloidosis for many years. The center later led the initial safety study of the international ANDROMEDA trial and contributed to its randomized phase, which tested the addition of daratumumab, an antibody that targets plasma cells, to a three-drug regimen. By blood and urine criteria, 53% of patients who received daratumumab achieved a complete response of the plasma-cell disorder, compared with 18% who received the three drugs alone. After about five years of follow-up, the patients treated with the daratumumab combination regimen also had better survival. Regulatory agencies worldwide approved this regimen as the first and only standard of care for AL amyloidosis.
In their 2026 review in Blood, ARTC investigators examined tools for early diagnosis, how sensitive tests can detect abnormal light chains at diagnosis and find signs of disease that persists after treatment. They also reviewed research into why some light chains are more likely to form amyloid. Features such as reduced protein stability and sugars attached at particular sites could help identify people at higher risk of developing AL amyloidosis who might benefit from closer follow-up and early intervention.
Transthyretin amyloidosis
Investigators at the Amyloidosis Research and Treatment Center (ARTC) at Policlinico San Matteo in Pavia have helped improve diagnosis and treatment for people with transthyretin amyloidosis (ATTR), a disease caused by deposits of the protein transthyretin. Their work spans hereditary ATTR, which can damage the peripheral nerves and heart, and wild-type ATTR, which mainly affects the heart in older adults.
Pavia investigators contributed to the 2016 international study that established when cardiac ATTR can be diagnosed without a heart biopsy. In patients with typical cardiac imaging findings, moderate or strong tracer uptake in the heart muscle on bone scintigraphy can establish ATTR when blood and urine tests show no evidence of a monoclonal protein. This distinction matters because light-chain (AL) amyloidosis can also produce uptake and requires different treatment. The Pavia team also contributed to work showing that some hereditary variants, such as Phe64Leu, can give a negative scan despite cardiac involvement. For patients who still need a biopsy, the center helped develop methods, including mass spectrometry, to identify the protein in the deposits.
Working with neurologists in Pavia, the center reviewed 150 patients with hereditary ATTR and found that nearly one in three had initially received a different diagnosis, most commonly an inflammatory neuropathy. The team led the development of European recommendations on genetic counseling, voluntary testing of relatives at risk, and regular follow-up of people who carry a disease-causing variant. A subsequent Italian multicenter study involving Pavia found that family screening detected disease at an earlier stage, when treatment can start before more extensive nerve or heart damage develops.
On the treatment front, the ARTC investigators, and particularly Dr. Laura Obici, contributed to the development of drugs, including transthyretin stabilizers, such as tafamidis and acoramidis, and suppressors of the synthesis of transthyretin, such as patisiran, vutrisiran, and eplontersen. An early study led by the ARTC showed that tafamidis stabilized transthyretin in patients with several less common hereditary variants. Pavia investigators helped design and conduct the international ATTR-ACT trial, which showed that tafamidis improved survival and reduced cardiovascular hospitalizations in ATTR cardiomyopathy. They also contributed to the pivotal inotersen trial, which showed that reducing transthyretin production in the liver could slow the progression of hereditary ATTR polyneuropathy. They participated in key studies that showed significant clinical benefits of the suppressors of transthyretin synthesis, named above. These drugs, stabilizers and suppressors of synthesis, have changed the face of transthyretin amyloidosis, improving the quality of life and survival. This short summary exemplifies the central role of clinical and basic research in improving care of systemic amyloidoses, diseases that lacked effective therapy until a few years ago and are now treatable, with a realistic perspective on a cure, particularly for patients diagnosed early.